No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 13 of the 33 quarters in the window, leaving 20 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 14.4x · 10Y median 8.3x · 69th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 34
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:21:43.622Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T13:21:43.622Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T13:21:43.622Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T13:21:43.622Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T13:21:43.622Z. Latest historical point 2026-10-05.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T13:21:43.622Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T13:21:43.622Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T13:21:43.622Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Eton Pharmaceuticals, Inc. (ETON) stock was $55.62 as of Oct 5, 2026, 4:00 PM EDT, up 0.47% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +177.7% · 3-year avg +140.4%/yr · 5-year avg +63.0%/yr
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Drug Manufacturers - Specialty & Generic · Deer Park, IL
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
0.31
Revenue Est.
$41.98M
Last Quarter Results
EPS
$0.43
vs Estimate
$0.19
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ETON | $1.52B | $55.62 | +0.47% | +177.71% | +63.04% | N/A | N/A |
| 2INVA | $1.52B | $20.64 | +0.68% | +17.98% | +4.52% | +6.43% | vs ETON |
| 3GHRS | $1.52B | $22.17 | -3.36% | +68.81% | +0.52% | N/A | vs ETON |
| 4BRVE | $1.51B | $21.35 | +0.38% | N/A | N/A | N/A | vs ETON |
| 5CERT | $1.57B | $10.07 | +7.59% | -22.86% | -21.31% | N/A | vs ETON |
| 6ANAB | $1.46B | $49.20 | +1.38% | +137.50% | +21.54% | N/A | vs ETON |
32.71
$37.59M
vs Estimate
$27.11M
Consensus Rating
Based on 4 analysts
Average Price Target
$71.00
+27.7% upside
Low
$68.00
Current
$55.62
High
$76.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.25 | $0.31 | $0.37 | 2 |
| Quarter ending Dec 2026 | $0.35 | $0.36 | $0.37 | 2 |
| Quarter ending Mar 2027 | $0.41 | $0.41 | $0.42 | 1 |
| Quarter ending Jun 2027 | $0.39 | $0.40 | $0.40 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $1.03 | $1.09 | $1.14 | 2 |
| FY 2027 | $1.80 | $2.10 | $2.39 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $41.10M | $41.98M | $42.87M | 2 |
| Quarter ending Dec 2026 | $45.29M | $45.86M | $46.43M | 2 |
| Quarter ending Mar 2027 | $49.56M | $50.36M | $51.30M | 1 |
| Quarter ending Jun 2027 | $53.50M | $54.36M | $55.37M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Dec 31, 2026, matching Key Metrics.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $148.29M | $149.71M | $151.14M | 3 |
| FY 2027 | $203.14M | $219.91M | $236.67M | 3 |
